Tag Archive for: Funding

Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program

Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b Deal is a major step forward for Fibrocor’s plans to develop FIB918, its monoclonal antibody for Alport Syndrome, a rare disease with very limited treatment options Fibrocor and MSRD intend […]

Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’

Oslo, 17 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that the Research Council of Norway has approved Lytix’s application for up to NOK14.3m (US$1.3m) of non-dilutive financial support from the ‘SkatteFUNN’ R&D tax incentive scheme for a project in respect of its lead […]

Aldena Therapeutics and Empa Awarded InnoSuisse Funding to Advance STAR Particles as a Novel Drug Delivery Technology for Dermatology

Boston, Massachusetts, April 26, 2023 – Aldena Therapeutics Inc. (Aldena), a private biotech company pioneering siRNA-based therapies for dermatological indications, and Empa, the Swiss Federal research institute for materials science and technology, have been awarded a joint 600’000 CHF grant by InnoSuisse, the Swiss Innovation Agency. This StarCURE grant seeks to co-develop microneedle particles as […]

AMSilk Announces Extension of Series C Financing to EUR 54M

Funding enables AMSilk to accelerate industrial scale-up and expand commercial operations of bio-fabricated silk protein materials Financing led by existing investors ATHOS (AT Newtec) with participation from Novo Holdings, Cargill, and MIG Capital. Munich, 4. April, 2023: AMSilk GmbH (“AMSilk”), the world’s first industrial supplier of bio-fabricated silk protein materials, today announced it has successfully raised […]

Evaluate Vantage shares biopharma predictions for 2023

In this report, Amy Brown, Edwin Elmhirst and Joanne Fagg of Evaluate Vantage discuss the outlook for biopharma in 2023.  According to the team, there is hope for an improvement in 2023 after the trials of the last two years, although few are expecting a dramatic recovery.   Check out the Evaluate team’s thoughts on the […]